NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No. 68; Photodynamic therapy for age-related macular degeneration, No. 155; Pegaptanib and ranibizumab for the treatment of age-related macular degeneration, and No. 294; Aflibercept solution for injection for treating wet age-related macular degeneration

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or
NA Coul /	appeal)
Manufacturers/sponsors	General
Bayer (aflibercept)	Allied Health Professionals Federation
Novartis (verteporfin, ranibizumab)	Board of Community Health Councils in
Pfizer (pegaptanib)	Wales
	British National Formulary
Patient/carer groups	Care Quality Commission
Action for Blind People	 Department of Health, Social Services
Afiya Trust	and Public Safety for Northern Ireland
Black Health Agency	Healthcare Improvement Scotland
Equalities National Council	 Medicines and Healthcare Products
Eyecare Trust	Regulatory Agency
Fight for Sight	 National Association of Primary Care
Macular Society	 National Pharmacy Association
Muslim Council of Britain	NHS Alliance
Muslim Health Network	NHS Commercial Medicines Unit
OBAC	NHS Confederation
RNIB	Scottish Medicines Consortium
SeeAbility	
Sense	Comparator manufacturers
South Asian Health Foundation	Moorfields Pharmaceuticals
Specialised Healthcare Alliance	(bevacizumab)
Thomas Pocklington Trust	Roche Products (bevacizumab)
Thomas i ocknington must	Royal Liverpool and Broadgreen
Professional groups	University Hospitals NHS Trust
British Geriatrics Society	Pharmacy (bevacizumab)
British Ophthalmic Anaesthesia	,
Society	Relevant research groups
	Cochrane Eyes and Vision Group
	Eye Hope
	Health Research Authority
Royal College of Nursing Royal College of Onbtholmalogists	 Institute of Ophthalmology, University
Royal College of Ophthalmologists Royal College of Dethalmologists	College London
Royal College of Pathologists	MRC Clinical Trials Unit
Royal College of Physicians	- Will Common Thais offic

NICE Technology Appraisal No. 68; Photodynamic therapy for age-related macular degeneration, No. 155; Pegaptanib and ranibizumab for the treatment of age-related macular degeneration, and No. 294; Aflibercept solution for injection for treating wet age-related macular degeneration

Issue date: May 2014 Page 1 of 2

- Royal Pharmaceutical Society
- Royal Society of Medicine
- United Kingdom Clinical Pharmacy Association

Others

- Department of Health
- NHS England
- NHS Leicester City CCG
- NHS Newham CCG
- Welsh Government

- National Eye Research Centre
- National Institute for Health Research
- Research Institute for the Care of Older People

Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

National Clinical Guideline Centre

Associated Public Health Groups

- Public Health England
- Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: May 2014 Page 2 of 2

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary. All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.

NICE Technology Appraisal No. 68; Photodynamic therapy for age-related macular degeneration, No. 155; Pegaptanib and ranibizumab for the treatment of age-related macular degeneration, and No. 294; Aflibercept solution for injection for treating wet age-related macular degeneration

Issue date: May 2014 Page 3 of 2